Pharmacology, Toxicology and Pharmaceutical Science
Abiraterone Acetate
20%
Adenocarcinoma
20%
Adverse Event
56%
Androgen
20%
Antitumor Activity
36%
Bevacizumab
37%
Breast Cancer
45%
Carboplatin
52%
Carcinoembryonic Antigen
20%
Castration Resistant Prostate Cancer
28%
Cetuximab
45%
Chemotherapy
99%
Clinical Trial
62%
Combination Therapy
20%
Digestive System Cancer
18%
Disease
84%
Docetaxel
42%
Doxorubicin
32%
Edrecolomab
22%
Eltrombopag
37%
Epidermal Growth Factor Receptor
19%
Gemcitabine
38%
Ibritumomab Tiuxetan
22%
Idiopathic Thrombocytopenic Purpura
78%
Immunoglobulin
19%
Iodine-131
42%
Malignant Neoplasm
62%
Maximum Tolerated Dose
39%
Metastatic Breast Cancer
32%
Metastatic Colorectal Cancer
30%
Metastatic Melanoma
22%
Monoclonal Antibody
100%
Neoplasm
99%
Neutropenia
21%
Non Small Cell Lung Cancer
53%
Nonhodgkin Lymphoma
76%
Overall Survival
51%
Paclitaxel
30%
Pharmacokinetics
61%
Phase I Trials
92%
Phase II Trials
40%
Placebo
29%
Prednisone
22%
Progression Free Survival
40%
Prostate Cancer
35%
Receptor
25%
Rituximab
48%
Solid Malignant Neoplasm
51%
Subcutaneous Injection
23%
Thrombocytopenia
23%
Medicine and Dentistry
Adverse Event
17%
Antibody-Drug Conjugate
15%
Arm
23%
Arsenic Trioxide
15%
Awareness
24%
B Cell
22%
Bendamustine
15%
Bevacizumab
30%
Breast Cancer
99%
Carboplatin
15%
CD20
15%
Chemotherapy
26%
Chemotherapy Regimens
13%
Clinical Trial
32%
Clinician
13%
COVID-19
17%
Diagnosis
24%
Diseases
32%
Eltrombopag
37%
Gemcitabine
15%
Glembatumumab Vedotin
15%
Glycoprotein
15%
Idiopathic Thrombocytopenic Purpura
67%
Immunoglobulin
12%
Infusion
12%
Iodine 131
22%
Letrozole
15%
Low and Middle Income Countries
24%
Low Drug Dose
25%
Malignant Neoplasm
46%
Metastatic Colorectal Cancer
22%
Metastatic Melanoma
15%
Monoclonal Antibody
34%
Neoplasm
47%
Non-Hodgkin Lymphoma
26%
Overall Survival
17%
Phase I Trials
15%
Placebo
17%
Platelet
42%
Postmenopause
15%
Prevalence
13%
Progression Free Survival
17%
Radiation Therapy
15%
Receptor
11%
Solid Malignant Neoplasm
15%
Subcutaneous Injection
12%
Thrombocytopenia
12%
Tositumomab
15%
Triple Negative Breast Cancer
18%
Veltuzumab
15%
Immunology and Microbiology
Antibody Drug Conjugate
15%
Antibody Response
25%
Antiidiotypic Antibody
15%
Arm
25%
B Cell
12%
Biological Product
9%
Blood Level
11%
Blood Plasma
13%
Carcinoembryonic Antigen
15%
CD16
10%
CD20
10%
Chimeric Antibody
10%
Cyclophosphamide
8%
Edrecolomab
15%
Etaracizumab
7%
Fc Receptor
17%
Glembatumumab Vedotin
15%
Glycoprotein
22%
Human Immunoglobulin
18%
Idiopathic Thrombocytopenic Purpura
38%
Immune Response
43%
Immunity
23%
Immunoglobulin G
8%
Immunoglobulin G1
8%
Immunoglobulin G4
9%
Immunology
71%
Interferon Type I
15%
Interleukin 2 Receptor
11%
Intravenous Immunoglobulin
21%
Intravenous Immunoglobulin Therapy
7%
Iodine-131
22%
Low Drug Dose
10%
Lupus Erythematosus
8%
Marginal Zone B-Cell
7%
Maximum Tolerated Dose
11%
Microbiome
15%
Monoclonal Antibody
47%
Murine
12%
Pharmacokinetics
32%
Plasma Half Life
9%
Platelet
54%
Platelet Count
11%
Rituximab
16%
Somatomedin
7%
T Cell
18%
Thrombocyte Membrane
14%
Tigatuzumab
7%
Trastuzumab
7%
Tumor Antigen
10%
Veltuzumab
7%